Cellectis, Janssen, and others plunge into cell therapy with the help of several genome-editing technologies, including TALENs and CRISPR/Cas9.
NIH Director Francis Collins today posted a position statement outlining a policy not to fund any use of gene editing technologies in human embryos.
Scientists from Emory University have found that Cas9 from Francisella novicida can inhibit viral protein production.
The data show that Phytophthora pathogens evolved effectors that bind to a conserved plant protein that controls small RNA biogenesis and processing.
The unique characteristics of mitochondrial genomes and diseases add a twist to the current discussions about heritable edits to the genome.
In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.
Cancer clinical trial patients settle with Anil Potti and Duke University.
A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.
Two Johns Hopkins researchers discuss the need for evidence-based data analysis.